Pfizer Inc
—- Market cap
- —
- Debt
- +$64.80B
- Cash
- −$1.14B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PFE stock price vs CAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CAT's multiple
Needs CAT P/E.
Implied fair value · at PFE's multiple
Needs PFE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
Bear
$10.17
Base
$12.82
Bull
$17.53
CATERPILLAR INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JOHNSON & JOHNSON
PFE vs JNJ
Merck & Co., Inc.
PFE vs MRK
AbbVie Inc.
PFE vs ABBV
BRISTOL MYERS SQUIBB CO
PFE vs BMY
ELI LILLY & Co
PFE vs LLY
AMGEN INC
PFE vs AMGN
DEERE & CO
PFE vs DE
CUMMINS INC
PFE vs CMI
Parker-Hannifin Corp
PFE vs PH
TEREX CORP
PFE vs TEX
AGCO CORP /DE
PFE vs AGCO
CNH Industrial N.V.
PFE vs CNHI
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PFE can reaccelerate revenue growth and sustain its high gross margin, then the current price looks attractive versus CAT because PFE trades at a much lower P/E, EV/EBITDA, and P/S; if not, the stock likely remains range-bound because its DCF range already overlaps the current price.
PFE trades at 19.3x P/E versus CAT at 45.6x, while also discounting CAT on P/S, EV/EBITDA, and EV/Revenue. The modeled implied price of $61.96 versus the current $26.20 suggests a large upside gap, but the valuation signal is tempered by PFE’s weaker growth profile and incomplete margin/quality data.
Supporting Metrics